Intraocular Pressure Elevation (Glaucoma)

Overview

Glaucoma is a group of progressive optic neuropathies in which the optic nerve is damaged, most often because of elevated intraocular pressure (IOP). While many people associate glaucoma solely with vision loss, the condition actually begins with subtle changes in the eye’s pressure dynamics. If untreated, the damage is irreversible and can lead to permanent blindness.

Who it affects: Glaucoma can occur at any age, but it is most common in adults over 40. Primary open‑angle glaucoma (POAG) – the most prevalent form – affects about 2.2 % of people aged 40 + in the United States, roughly 3 million individuals. Women are slightly more likely than men to develop POAG, while angle‑closure glaucoma is more common in Asian populations and in people over 60.

Global prevalence: According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness worldwide, affecting an estimated 76 million people in 2020 and projected to increase to over 111 million by 2040 as populations age.^{[1] WHO, Global Vision Data 2022}

Symptoms

Glaucoma is often called the “silent thief of sight” because early stages may have no noticeable symptoms. When symptoms appear, they vary by type.

• Gradual peripheral vision loss: Most common in open‑angle glaucoma; patients notice difficulty seeing objects at the sides, especially in low‑light conditions.
• Tunnel vision: As damage progresses, field loss narrows, creating a “tunnel” effect.
• Halos around lights: Frequent in angle‑closure glaucoma; halos may be accompanied by colored rings.
• Eye pain or redness: Sudden, severe pain often signals an acute angle‑closure attack.
• Headache: Typically located behind the eyes and may worsen with eye movement.
• Nausea or vomiting: Occurs primarily with acute angle‑closure episodes due to rapid IOP rise.
• Blurred vision: Temporary or persistent blurring can accompany IOP spikes.
• Seeing “floaters” or flashes: Not typical of glaucoma but may coexist with other eye conditions; still worth reporting.

Because many of these signs appear late, regular eye exams are essential for early detection.

Causes and Risk Factors

Underlying mechanisms

Intraocular pressure is maintained by a balance between the production and drainage of aqueous humor, a clear fluid that nourishes the front of the eye. Elevated IOP occurs when drainage through the trabecular meshwork (open‑angle) or the angle between the iris and cornea (angle‑closure) becomes impaired, leading to fluid buildup.

Risk factors

• Age: Risk doubles every decade after age 40.
• Family history: First‑degree relatives with glaucoma increase risk 2–4×.
• Ethnicity: African‑American (higher POAG risk) and Asian (higher angle‑closure risk) populations.
• High myopia (nearsightedness): Stretched optic nerve fibers are more vulnerable.
• Thin corneas: May mask true IOP readings and correlate with increased risk.
• History of eye trauma or surgery: Can damage drainage structures.
• Corticosteroid use: Prolonged topical, oral, or inhaled steroids can raise IOP.
• Systemic conditions: Diabetes, hypertension, and hypothyroidism have modest associations.
• Low blood flow to the optic nerve: Conditions such as sleep apnea can contribute.

Diagnosis

Accurate diagnosis combines a thorough history, visual function testing, and imaging of the optic nerve.

Key Tests

• Tonometry: Measures IOP. Goldmann applanation tonometry remains the gold standard; normal range is 10–21 mm Hg.
• Gonioscopy: Visualizes the angle structures with a special lens to differentiate open vs. closed angles.
• Ophthalmoscopy (fundoscopy): Direct examination of the optic disc for cupping or thinning.
• Perimetry (visual field testing): Detects peripheral vision loss; the Humphrey 24‑2 test is commonly used.
• Optical coherence tomography (OCT): Provides high‑resolution cross‑sectional images of retinal nerve fiber layer (RNFL) thickness.
• Pachymetry: Measures central corneal thickness; important for interpreting tonometry results.
• Imaging (Heidelberg Retina Tomograph or scanning laser polarimetry): Offers additional structural detail of the optic nerve head.

Diagnosis often requires at least two separate tests showing consistent findings of elevated IOP and/or optic nerve damage.

Treatment Options

Because glaucomatous damage is irreversible, treatment focuses on lowering IOP to a level that halts progression.

Medications

• Prostaglandin analogues (e.g., latanoprost, bimatoprost): Increase outflow through the uveoscleral pathway; once‑daily dosing.
• Beta‑blockers (e.g., timolol, betaxolol): Reduce aqueous production; contraindicated in asthma or severe COPD.
• Alpha‑agonists (e.g., brimonidine): Dual action—decrease production & increase outflow; may cause dry mouth.
• Carbonic anhydrase inhibitors (e.g., dorzolamide, oral acetazolamide): Lower production; oral form used for acute IOP spikes.
• Rho‑kinase inhibitors (e.g., netarsudil): Newer class that improves trabecular outflow.
• Fixed‑dose combination drops: Reduce pill burden and improve adherence.

Typical goal: reduce IOP by 20‑30 % from baseline.

Surgical & Laser Procedures

• Selective Laser Trabeculoplasty (SLT): Low‑energy laser applied to trabecular meshwork; effective for many POAG patients, often delaying need for surgery.
• Argon Laser Peripheral Iridotomy (ALPI): Creates a small hole in the peripheral iris to relieve angle‑closure.
• Trabeculectomy: Creates a new drainage pathway (filtering bleb); gold standard for advanced disease.
• Tube shunt (e.g., Ahmed, Baerveldt): Small silicone tube implanted to divert fluid; used when trabeculectomy fails or in complex cases.
• Minimally invasive glaucoma surgery (MIGS): Devices (e.g., iStent, Hydrus) placed via a small incision; lower risk but modest IOP reduction.

Lifestyle & Adjunct Measures

• Regular aerobic exercise (e.g., brisk walking) can lower IOP by 2‑4 mm Hg.
• Limit caffeine intake; excessive caffeine may raise IOP temporarily.
• Avoid high‑altitude exposure or rapid ascent without medical advice—hypoxia can increase IOP.
• Adhere strictly to medication schedules; missed doses accelerate progression.

Living with Intraocular Pressure Elevation (Glaucoma)

Managing glaucoma is a lifelong commitment that blends medical care with daily habits.

Practical tips

• Medication adherence: Use a pill‑box or an eye‑drop reminder app; keep a log of any side effects.
• Routine eye exams: At least every 6–12 months, or more often if disease is progressing.
• Protect your eyes: Wear UV‑blocking sunglasses and safety goggles during sports or home repairs.
• Healthy diet: Antioxidant‑rich foods (leafy greens, berries) support optic nerve health; omega‑3 fatty acids may be beneficial.
• Manage systemic health: Keep blood pressure, blood sugar, and cholesterol under control.
• Stay informed: Join a support group or reputable online community for updates on new therapies.

Prevention

Because some risk factors (age, genetics) cannot be changed, prevention focuses on modifiable elements.

• Schedule a comprehensive eye exam by age 40, or earlier if you have risk factors.
• Limit prolonged steroid use; discuss alternative treatments with your physician.
• Maintain a healthy weight and exercise regularly.
• Control systemic diseases such as diabetes and hypertension.
• Avoid smoking; tobacco use is linked to reduced ocular blood flow.
• Stay hydrated, but avoid excessive fluid intake right before bedtime, which can raise nocturnal IOP.

Complications

If IOP remains uncontrolled, the following complications may arise:

• Progressive visual field loss: Leads to difficulty navigating stairs, driving, or reading.
• Total blindness: Rare in well‑managed cases but possible with advanced, untreated disease.
• Secondary ocular conditions: Cataract formation from steroid use or surgery, corneal decompensation after certain procedures.
• Psychological impact: Depression and anxiety are more common in patients with significant vision loss.

When to Seek Emergency Care

References

1. World Health Organization. “Global Vision Data 2022.” WHO Vision Programme, 2022.
2. Mayo Clinic. “Glaucoma – Symptoms and Causes.” 2024.
3. American Academy of Ophthalmology. “Preferred Practice Pattern: Primary Open‑Angle Glaucoma.” 2023.
4. National Eye Institute (NEI). “Facts About Glaucoma.” Updated 2023.
5. Cleveland Clinic. “Glaucoma Treatment Options.” 2024.
6. JAMA Ophthalmology. “Long‑Term Outcomes of MIGS Procedures.” 2022.